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Background: Long non-coding RNAs (lncRNA) play an important role in carcinogenesis; knowledge on lncRNA
expression in renal cell carcinoma is rudimental. As a basis for biomarker development, we aimed to explore the
lncRNA expression profile in clear cell renal cell carcinoma (ccRCC) tissue.
Results: Microarray experiments were performed to determine the expression of 32,183 lncRNA transcripts
belonging to 17,512 lncRNAs in 15 corresponding normal and malignant renal tissues. Validation was performed
using quantitative real-time PCR in 55 ccRCC and 52 normal renal specimens. Computational analysis was
performed to determine lncRNA-microRNA (MiRTarget2) and lncRNA-protein (catRAPID omics) interactions. We
identified 1,308 dysregulated transcripts (expression change >2-fold; upregulated: 568, downregulated: 740) in
ccRCC tissue. Among these, aberrant expression was validated using PCR: lnc-BMP2-2 (mean expression change:
37-fold), lnc-CPN2-1 (13-fold), lnc-FZD1-2 (9-fold), lnc-ITPR2-3 (15-fold), lnc-SLC30A4-1 (15-fold), and lnc-SPAM1-6
(10-fold) were highly overexpressed in ccRCC, whereas lnc-ACACA-1 (135-fold), lnc-FOXG1-2 (19-fold), lnc-LCP2-2
(2-fold), lnc-RP3-368B9 (19-fold), and lnc-TTC34-3 (314-fold) were downregulated. There was no correlation
between lncRNA expression with clinical-pathological parameters. Computational analyses revealed that these
lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization, and processing
of RNA. Small interfering RNA (siRNA)-mediated knockdown of lnc-BMP2-2 and lnc-CPN2-1 did not influence cell
proliferation.
Conclusions: We identified many novel lncRNA transcripts dysregulated in ccRCC which may be useful for novel
diagnostic biomarkers.Background
Renal cell carcinoma (RCC) is one of the most common
malignancies; its incidence is varying substantially
worldwide: RCC incidence is high in Europe and North
America and low in Asia and South America [1]. Today,
many small-sized renal tumors are diagnosed; however,
imaging modalities do not allow precise differentiation
between renal cell carcinoma and non-malignant renal
tumors. Performing tumor biopsy and histopathological
classification is sometimes challenging, and definitive
exclusion of malignancies still requires surgical ex-
ploration. As active surveillance protocols for small
renal lesions find the way into daily clinical practice, a
better estimation of tumor aggressiveness becomes* Correspondence: joerg.ellinger@ukb.uni-bonn.de
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unless otherwise stated.necessary. Thus, identifying novel biomarkers would
be helpful for the management of patients with renal
tumors.
Nucleic acids are under discussion as potential bio-
markers for patients with RCC [2]. Long non-coding
RNAs (lncRNA) are a class of RNA molecules arbitrarily
defined as being longer than 200 nucleotides and not
translated into a protein. Initially, it was thought that
lncRNAs represent transcriptional noise, but it is now-
adays recognized that lncRNAs may have biological
roles. They are regulating imprinting, dosage compensa-
tion, cell cycle, pluripotency, retrotransposon silencing,
and meiotic entry, for example [3]. However, knowledge
on lncRNA expression and their function is still in its
infancy, but lncRNA expression seems to be highly
tissue and tumor specific [4]. So far, few are known
on lncRNAs expression in RCC [5-8]. We thereforeral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion of 32,183 lncRNA transcripts in a cohort of patients
with clear cell RCC (ccRCC) to determine a comprehen-
sive lncRNA profile.Results
Microarray: screening for aberrantly expressed lncRNAs
A gene expression microarray was used to identify dysreg-
ulated lncRNAs in 15 corresponding tumor and normal
renal tissue samples as a discovery cohort. Among the
32,183 analyzed lncRNA transcripts, we observed differen-
tial expression (fold change >2) in 1,308 transcripts: 568
lncRNA transcripts were upregulated and 740 were down-
regulated in ccRCC samples. The 20 most differentially
expressed lncRNAs in ccRCC and normal renal tissue are
listed in Table 1. A hierarchical cluster analysis based on
centered Pearson correlation coefficient was performed to
determine different expression profiles in ccRCC and nor-
mal tissue. As shown in Figure 1, the lncRNA expression
profile allowed distinguishing cancerous and normal tissue
samples highly accurately.Table 1 List of 20 differentially expressed lncRNAs in
renal cell carcinoma identified using a microarray
screening in each 15 normal and malignant renal tissues





lnc-TTC34-3 −6.585 lnc-CPN2-1 5.966
lnc-ACACA-1 −6.486 lnc-BMP2-2 4.787
lnc-LCP2-2 −5.771 lnc-DGCR6-2 4.659
lnc-AC068473.1-2 −5.654 lnc-ITPR2-3 4.379
lnc-MED10-7 −5.145 lnc-SLC30A4-1 4.150
lnc-TMEM18-8 −4.880 lnc-NR2E1-1 4.131
lnc-ATP1A1OS-2 −4.770 lnc-FZD1-2 4.019
lnc-FOXG1-2 −4.485 lnc-DGCR6-2 3.920
lnc-TRAT1-2 −4.484 lnc-PADI1-1 3.904
lnc-RP3-368B9.1.1-1 −4.453 lnc-SPAM1-6 3.516
lnc-IFRD2-1 −4.440 lnc-PRRC2C-1 3.508
lnc-TBCCD1-1 −4.369 lnc-MYC-2 3.483
lnc-C15orf2-2 −3.981 lnc-CDRT15L2-1 3.479
lnc-ATP8A1-1 −3.960 lnc-SCRG1-1 3.275
lnc-LY86-3 −3.876 lnc-TMEM30B-5 3.260
lnc-SCN2A-2 −3.787 lnc-RCBTB2-1 3.205
lnc-ST6GALNAC3-1 −3.786 lnc-AHR-1 3.034
lnc-MIS18BP1-1 −3.557 lnc-DLX2-4 2.903
lnc-RASL11B-2 −3.532 lnc-HPS3-2 2.720
lnc-RACGAP1-2 −3.528 lnc-RCBTB2-3 2,709Real-time PCR: validation of expression profiling
In order to confirm aberrant lncRNA expression, we de-
termined the expression of 13 lncRNAs in an independent
validation cohort of ccRCC (n = 55) and normal (n = 52)
renal tissue samples. The selection of representative
lncRNAs for validation was based on the degree of dys-
regulation in the microarray (six upregulated and five
downregulated lncRNA; in addition two non-regulated
lncNRA). As expected, lnc-BMP2-2 (mean: 37-fold), lnc-
CPN2-1 (13-fold), lnc-FZD1-2 (9-fold), lnc-ITPR2-3
(15-fold), lnc-SLC30A4-1 (15-fold), and lnc-SPAM1-6 (10-
fold; all p < 0.001) were highly overexpressed in RCC,
whereas lnc-ACACA-1 (135-fold), lnc-FOXG1-2 (19-fold),
lnc-LCP2-2 (2-fold), lnc-RP3-368B9 (19-fold), and lnc-
TTC34-3 (314-fold) were downregulated (all p < 0.001).
Both, lnc-ERCC5-1 (p = 0.401) and lnc-RP11-480I12.4.1-1
(p = 0.731) were—as observed in the microarray studies—
not dysregulated in tumor samples. The lncRNA expression
levels allowed highly sensitive and specific discrimination
between RCC and control subjects as determined by using
ROC analyses: the area under the curve was >0.9 for all
dysregulated samples, especially lnc-CPN2-1 overexpres-
sion allowed molecular identification of RCC tissue (AUC
0.942, 95% confidence interval 0.884–1.000). See Figure 2
and Table 2.
We also analyzed whether lncRNA expression levels
were correlated with poor prognostic parameters; the
Bonferroni method was applied to correct for multiple hy-
pothesis testing (adjusted significance value p < 0.0083).
None of the lncRNAs was significantly correlated with sta-
ging nor grading. However, there was a tendency towards
lower lnc-ERCC5-1 (p = 0.034) and RP3-368B9 (p = 0.016)
levels in Fuhrman grade 3/4 tumors, lower lnc-ERCC5-1
(p = 0.026) expression in vascular invasive tumors, and ad-
vanced AJCC stage in samples with low lnc-RP3-368B9
(p = 0.011). lncRNAs were not associated with progres-
sion-free survival, overall survival or cancer-specific sur-
vival (all p > 0.05, data not shown), as determined using
Cox regression analysis.
siRNA-mediated lncRNA knockdown
We next treated Caki-1, Caki-2, and A-498 RCC cell
lines with small interfering RNA (siRNA) targeting lnc-
BMP2-2 and lnc-CPN2-1; see Figure 3. lnc-BMP2-2
expression was significantly (p < 0.05) decreased in
siRNA-treated Caki-1 and Caki-2 (only siRNA #2) cells;
it was basically unexpressed in A-498 cells. lnc-CPN2-1
was also decreased in Caki-2 cells (p < 0.05). Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) expression
was significantly reduced in all cell lines (not shown);
the negative controls did not change gene expression.
However, the EZ4U test did not show any changes in
cellular proliferative activity after siRNA-mediated
lncRNA knockdown. See Figure 4.
Figure 1 lncRNA expression profiling. The expression of 32,183 lncRNA transcripts was determined in 15 corresponding clear cell renal carcinoma
(ccRCC) and normal renal tissue samples. The expression profile of 25 different lncRNA transcript variants allows accurate discrimination of normal and
malignant renal tissue as shown in the heatmap. All ccRCC tissues (green bar above the heatmap) and normal renal tissues (red bar) are located in a
separate cluster.
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protein interaction
The MiRTarget2 algorithm [9] was used to predict micro-
RNA seeds within the validated lncRNA transcripts. Most
transcripts do not have any (lnc-BMP2-2; lnc-FZD1-2;
lnc-ITPR2-3:1; lnc-SPAM1-6; lnc-TTC34-4) or only few
(lnc-ACACA-1: miR-4652-3p, miR-5001-3p, miR-4753-
3p; lnc-CPN2-1: miR-149-3p; lnc-LCP2-2: miR-3191-5p;
lnc-SLC30A4-1: miR-4772-5p) predicted targeting micro-
RNAs with—so far—unknown functions. lnc-FOXG1-2has multiple predicted target microRNAs (miR-3662,
miR-3120-5p, miR-519c-3p, miR-519a-3p, miR-548ag,
miR-4282, miR-519b-3p, miR-458 m, miR-3163, miR-
4658, miR-676-5p, miR-3973). It was reported that
lncRNAs can act as a microRNA sponge by binding spe-
cific microRNAs and thereby by interfering with their role
as regulator of gene expression [10]. However, none of the
predicted microRNA targets of FOXG1-2 was correlated
to FOXG1-2 levels in a cohort of each ten normal and
malignant renal tissue samples (data not shown; miR-
Figure 2 (See legend on next page.)
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Figure 2 Validation of lncRNA dysregulation. The expression of 13 target lncRNAs in renal cell carcinoma (red) and normal renal (green) tissue
was validated using quantitative real-time PCR; the expression levels were normalized using ACTB and PPIA as reference genes. We confirmed
significant (all p < 0.001) overexpression of lnc-BMP2-2 (B), lnc-CPN2-1 (C), lnc-FZD1-2 (F), lnc-ITPR2-3 (G), lnc-SLC30A6-1 (K), and lnc-SPAM1-6
(L) in renal cell carcinoma, whereas lnc-ACACA-1 (A), lnc-FOXG1-2 (E), lnc-LCP2-2 (H), lnc-RP3-368B9 (I), and lnc-TTC34-3 (M) were significantly
downregulated (all p < 0.001); lnc-ERCC5-1 (D, p = 0.401) and lnc-RP11-480I12.4.1-1 (J, p = 0.731) were not different in malignant and normal renal
tissue. Receiver operator characteristic (N) analyses demonstrate excellent discrimination of the lncRNAs between both cohorts (area under the
curve 0.90–0.94).
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4284, miR-4658: all p > 0.1). MicroRNA expression was
similar in RCC and normal renal tissue (all p > 0.5).
Furthermore, we determined lncRNA-protein interac-
tions using the catRAPID omics algorithm [11]. Numer-
ous lncRNA-protein interactions (n = 91) are predicted
for all transcripts (see Additional file 1: Table S2); the
cellular functions of proteins with a ranking score >2.5
were next explored using GeneMANIA [12]. The inter-
acting networks are mainly related to splicing, binding,
transport, localization, and processing of RNA but also
transcription and translation (see Table 3; Additional file 2:
Table S3).
Discussion
lncRNA are important regulators of gene expression
during genetic information processing in living cells and
interact with major cellular pathways (e.g. proliferation,
differentiation, apoptosis). Thereby, they are involved in
carcinogenesis of many human malignancies [13], but so
far, knowledge about lncRNA expression in RCC is
limited [5-8]. We determined the expression of 32,183
lncRNA transcripts belonging to 17,512 lncRNAs in 15
corresponding normal and malignant renal tissues,
thereby providing the most comprehensive analysis ofTable 2 Receiver operator characteristic analyses for
discrimination of normal and malignant renal tissue





lnc-FZD1-2 upregulation 0.931 0.871–0.991
lnc-SLC30A4-1 upregulation 0.942 0.883–1.000
lnc-BMP2-2 upregulation 0.912 0.843–0.981
lnc-SPAM1-6 upregulation 0.900 0.830–0.969
lnc-ITPR2-3 upregulation 0.941 0.887–0.994
lnc-CPN2-1 upregulation 0.942 0.884–1.000
lnc-TTC34-3 downregulation 0.990 0.973–1.000
lnc-ACACA-1 downregulation 0.966 0.923–1.000
lnc-LCP2-2 downregulation 0.955 0.906–1.000
lnc-FOXG1-2 downregulation 0.954 0.911–0.997
lnc-RP3-368B9.1.1-1 downregulation 0.938 0.892–0.984lncRNA expression in RCC up to now. We observed dif-
ferential expression of 1,308 lncRNA transcripts (defined as
expression differences >2-fold) corresponding to 4.1% of
the studied transcripts. The expression of lncRNAs was
successfully validated for upregulated (lnc-BMP2-2, lnc-
CPN2-1, lnc-FZD1-2, lnc-ITPR2-3, lnc-SLC30A4-1, lnc-
SPAM1-6), downregulated (lnc-ACACA-1, lnc-FOXG1-2,
lnc-LCP2-2, lnc-RP3-368B9, lnc-TTC34-3), and unregu-
lated (lnc-ERCC5-1, lnc-RP11-480I12.4.1-1) transcripts
using qPCR in a cohort of 55 ccRCC and 52 normal renal
specimen, thus the specificity of the microarray results is
confirmed. Two recent studies investigated the lncRNA
expression profile of RCC tissues using microarray tech-
nologies, but samples sizes were small (n = 4 [5]; n = 6 [6];
n = 11 [7]), thereby limiting powerful statistical analysis;
furthermore, the analyses were limited to a set of 984
lncRNAs in the Fachel study [7]. During later courses of
our study, Malouf et al. [8] re-analyzed the data obtained
in The Cancer Genome Atlas project and identified 1,934
lncRNA expressed in RCC. The catalog of the differen-
tially expressed lncRNAs varied in the profiling studies,
but notably, all studies demonstrated a tendency towards
an increased ratio of down- to upregulated lncRNAs [6,7].
Earlier studies linked aberrant expression of individual
lncRNAs to RCC in small-scaled studies (n ≤ 12; i.e. GAS5,
also termed SERPINC1 [8,14]; aHIF [15]; MALAT1 [8]);
we could not confirm GAS5 downregulation in our micro-
array study; aHIF and MALAT1 was not deregulated.
lncRNAs could serve as diagnostic and prognostic bio-
markers: The distinct overexpression of lncRNAs in RCC
could be used for the development of a non-invasive diag-
nostic biomarker. We demonstrated distinct (>10-fold)
expression level differences for a number of lncRNAs
including lnc-ACACA-1, lnc-BMP2-2, lnc-CPN2-1, lnc-
FOXG1-2, lnc-FZD1-2, lnc-ITPR2-3, lnc-RP3-368B9,
lnc-SLC30A4-1, lnc-SPAM1-6, and lnc-TTC34-3; if
expression differences are validated by independent re-
searchers, these lncRNAs could represent diagnostic bio-
markers. lncRNAs are detectable in bodily fluids and may
thereby serve for cancer diagnosis: The PROGENSA®
PCA3 Assay utilizes the detection of the lncRNA PCA3 in
urine as diagnostic biomarker for prostate cancer [16].
Furthermore, plasma levels of HULC were increased in
hepatocellular carcinoma [17], H19 in gastric cancer [18],
and MALAT-1 in prostate cancer [19] patients.
Figure 3 lncRNA expression after siRNA-mediated lncRNA knockdown. Expression of lnc-BMP2-2 (A) and lnc-CPN2-1 (B) was manipulated
using specific siRNA in Caki-1, Caki-2, and A-498 renal cell carcinoma cell lines. A-498 did not express lnc-BMP2-2. lnc-BMP2-2 expression was
significantly (p < 0.05) decreased in siRNA-treated Caki-1 and Caki-2 cells; lnc-CPN2-1 was also decreased in Caki-2 cells.
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Fachel et al. [7] reported a 26-gene lncRNA expression
profile, but not a single lncRNA, associated with the sur-
vival of ccRCC patients. However, the small sample size
(n = 16) and the lack of a validation cohort limit the in-
formative value of the study [7]. Malouf et al. [8] identi-
fied four lncRNA expression clusters among the study
cohort, and the survival was significantly reduced in one
subgroup (C2). We did not observe a correlation of
lncRNAs (used in the validation study) with any clinico-
pathological parameter nor survival data. Reasons for
the failure to identify prognostic relevant lncRNAs in-
clude: (i) a microarray study not powered for the identi-
fication of expression differences in localized (n = 5) and
advanced RCC (n = 10), (ii) the selection of lncRNAs for
validation based on the differential expression of tumor
and normal tissue samples, and (iii) the high number of
patients with localized ccRCC (56% AJCC stage 1 or 2)
in the validation cohort. We expect that future studies
designed to identify prognostic relevant lncRNAs in
RCC patients will be able to present some candidates,
because altered expression of specific lncRNAs was pre-
dictive of cancer-specific survival in former studies on
other human malignancies; i.e. upregulation of HOTAIR
in breast cancer [20] and SChLAP1 in prostate cancer
patients [21] was associated with a poor prognosis.
As interest in lncRNA research has increased a short
time ago, the function of lncRNAs remains largely un-
known, but involvement in many fundamental cellular
processes is assumed [13]. The short half-life time (<2 h)
of nuclear lncRNA predisposes for regulative functions
[22,23]. We performed in silico analyses to point out pu-
tative functions of dysregulated lncRNAs: (i) lncRNA
may act as miRNA sponge (e.g. miR-372 expression is
downregulated by the lncRNA HULC [24]). However,
the expression levels of several FOXG1-2 targetmicroRNAs were not correlated to the level of FOXG1-
2, thus we cannot confirm such a role for the investigated
lncRNAs. (ii) Furthermore, lncRNA may function via
lncRNA-protein interactions [25]. Using catRAPID omcis
[11], we identified putative 91 lncRNA-protein interac-
tions for the dysregulated lncRNAs (lnc-ACACA-1,
lnc-BMP2-2, lnc-CPN2-1, lnc-FOXG1-2, lnc-FZD1-2, lnc-
ITPR2-3, lnc-LCP2-2, lnc-RP3-368B9, lnc-SLC30A4-1,
lnc-SPAM1-6, lnc-TTC34-3). Most of these proteins are
functioning in splicing, binding, transport, localization,
transcription, translation, and processing of RNA. Provid-
ing experimental evidence beyond in silico predictions is
necessary in future studies.
Somewhat surprisingly, neither siRNA-mediated knock-
down of lncRNA-CPN2-2 nor lnc-BMP2-2 resulted in a
significant reduction of cell proliferation. However, the
lncRNA knockdown was of moderate success (relative ex-
pression change in siRNA-treated cell lines 2- to 5-fold,
despite of the extensive optimization of siRNA treatment
in preliminary experiments), and thus the toxicity of the
transfection reagent may inhibit determining the func-
tional relevance of both lncRNAs. Many lncRNAs regu-
late nuclear events and must therefore be localized in
the nucleus [26]. As is known, the knockdown of nu-
clear RNAs is often difficult [27], and therefore our ef-
forts to determine the functional relevance of lncRNAs
failed.
Conclusions
In summary, our study reveals that dysregulation of ap-
proximately 4% of the lncRNA transcripts occurs in
ccRCC, and altered lncRNA expression may modulate
fundamental cellular processes. lncRNA profiles allow to
accurately distinguish ccRCC and normal renal tissue.
Thus, lncRNAs may be used as non-invasive biomarker
for RCC patients.
Figure 4 Cell proliferation after siRNA-mediated lncRNA knockdown.
The EZ4U test was applied for cell proliferation testing; proliferative
activity was not changed in any renal cell carcinoma cell line
(A, A-498; B, Caki-1; C, Caki-2).
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Patients
Biomaterials including fresh-frozen tissues are prospect-
ively collected in the Biobank at the CIO Köln Bonn at
the Universitätsklinikum Bonn according to standard
operating procedures. Tissue from patients undergoing
radical nephrectomy or nephron-sparing surgery was
snap frozen, and samples from tumor and normal renal
tissue were stored at liquid nitrogen. Hematoxylin- and
eosin-stained sections were performed to confirm the
histology of the samples. The final histological diagnosis
was made on the formalin-fixed paraffin-embedded tis-
sue samples. All cases used in this study were reviewed
by an experienced uropathologist; the TNM classifica-
tion (7th edition from 2009) was applied. We used adiscovery cohort with 15 patients (ccRCC and adjacent
normal renal tissue) for screening 32,183 lncRNA tran-
scripts; the independent validation cohort consisted of
55 ccRCC and 52 normal renal tissue samples. The de-
tailed clinical-pathological parameters are reported in
Table 4. All patients gave written informed consent prior
collection of biomaterials. The study was approved by
the Ethikkommission at the Universitätsklinikum Bonn
(number: 280/12).
Cell culture and siRNA experiments
The cell lines Caki-1, Caki-2, and A-498 were obtained
from the DSMZ (Braunschweig, Germany). All cell lines
were maintained at 37°C, 5% CO2 in RPMI 1640 culture
medium, supplemented with 10% heat-inactivated fetal
calf serum and 2 mM of glutamine (PAA, Pasching,
Austria). The knockdown of lnc-BMP2-2 (#1: sense
GCG-UUU-UAA-UGU-CCA-CCA-Att, antisense UUG-
GUG-GAC-AUU-AAA-ACG-Caa; #2: sense GAA-AGA-
GAC-UGA-AUA-AUU-Att, antisense UAA-UUA-UUC-
AGU-CUC-UUU-Ctc) and lnc-CPN2-1 (#1: sense CAC-
UCA-UCU-UUA-AAU-UAG-Att, antisense UCU-AAU-
UUA-AAG-AUG-AGU-Gat; #2: sense CAA-UGA-AAC-
AGA-ACA-GAU-Att, antisense UAU-CUG-UUC-UGU-
UUC-AUU-Gtt) was performed with individually designed
Ambion Silencer Select siRNAs (Life Technologies, Foster
City, CA, USA); two different siRNAs were designed for
each target. In addition, negative controls (transfection
reagent without siRNA; Silencer Select Negative Control
siRNA #1) and a positive control (Silencer GAPDH Posi-
tive Control siRNA) were used. The cell lines were seeded
at 2.5 × 105 cells/well (6-well plate), and a forward trans-
fection using the Screenfect Transfection Kit (Genaxxon,
Ulm, Germany) with a siRNA concentration of 20 pmol
was performed according to the manufacturer’s recom-
mendations. The transfection complex was replaced after
24 h with RPMI medium and incubated for up to 72 h.
siRNA experiments were confirmed in three independent
experiments.
Cell proliferation assay
The cell lines were seeded at a concentration of 1.5 × 104
cells per well into a 96-well plate. After forward transfec-
tion (siRNA concentration 1.2 pmol), the cells were cul-
tured up to 72 h to determine the proliferative activity
after siRNA-mediated knockdown of lnc-BMP2-2 and lnc-
CPN2-1. The EZ4U assay (Biomedica, Vienna, Austria)
was used to determine cell viability using a 340 ATTC
Spectra Thermo SLT photometer (Crailsheim, Germany)
according to the manufacturer’s protocol.
RNA isolation
Fresh-frozen tissue samples (approximately 50 mg) were
cut on liquid nitrogen and homogenized with Yttrium
Table 3 Computationally predicted functions by lncRNA-protein interactions
Predicted function lnc-ACACA-1 lnc-BMP2-2 lnc-CPN2-1 lnc-FOXG1-2 lnc-FZD1-2 lnc-ITPR2-3 lnc-LCP2-2 lnc-RP3-368B9.1.1-1 lnc-SLC30A4-1 lnc-SPAM1-6 lnc-TTC34-3
mRNA processing X X X X X X X X X X X
mRNA/RNA splicing X X X X X X X X X X X
mRNA binding X X X X X X X X X
RNA localization X X X X X X X X
Ribonucleoprotein complex X X X X X X X
RNA transport X X X X X X X
Transcription X X X X X X X
Posttranscriptional regulation X X X X X X
mRNA/RNA stabilization X X X X X
DNA binding X X X
Translation X X X
Protein localization X
rRNA processing X









Table 4 Summary of clinicopathological parameters of
the study cohort
Screening cohort Validation cohort
n = 15 (%) Cancer
n = 55 (%)
Normal
n = 52 (%)
Sex
Male 10 (66.6) 37 (67.3) 36 (69.2)
Female 5 (33.3) 18 (33.7) 16 (30.8)
Age
Mean 61.2 62.9 62.1
Min-max 43–86 36–86 36–86
Pathological stage
pT1 4 (26.7) 29 (52.7) n.a.
pT2 2 (13.3) 7 (12.7) n.a.
pT3 9 (60.0) 18 (32.7) n.a.
pT4 0 (0) 1 (1.8) n.a.
Vascular invasion 7 (46.7) 16 (29.1) n.a.
Lymph node metastasis 0 (0) 2 (3.6) n.a.
Distant metastasis 1 (6.7) 7 (12.7) n.a.
AJCC staging group
I 4 (26.7) 26 (47.3) n.a.
II 1 (6.7) 5 (9.1) n.a.
III 9 (60.0) 16 (29.1) n.a.
IV 1 (6.7) 8 (14.5) n.a.
Fuhrman grading
Grade 1 2 (13.3) 4 (7.3) n.a.
Grade 2 11 (73.3) 41 (74.5) n.a.
Grade 3 2 (13.3) 9 16.3) n.a.
Grade 4 0 (0) 1 (1.8) n.a.
n.a. not applicable.
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Warmensteinach, Germany) using a Precellys®24 tissue
homogenizer (Peglab, Erlangen, Germany). Total RNA
was then isolated using the mirVana miRNA Isolation Kit
(Ambion, Foster City, CA, USA) according to the manu-
facturer’s recommendation. To remove residual DNA
fragments, we treated the isolate twice with DNase (DNA-
free Kit, Ambion). RNA quantity was determined with a
NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). RNA integrity was measured in
samples used for microarray experiments using the
Bioanalyzer 2100 with a RNA 6000 Nano Kit (Agilent
Technologies, Santa Clara, CA, USA); only samples with a
RIN >6 were used. RNA degradation was excluded by
agarose gel electrophoresis in samples used for PCR.
Microarray
The microarray experiments were performed by Biogazelle
(Zwijnaarde, Belgium) as a contract service. RNA isolatesfrom 15 corresponding normal renal and ccRCC tissues
(100 ng total RNA) were sent on dry ice to Biogazelle. A
custom microarray (Agilent SurePrint G3 technology)
based on LNCipedia 2.1 [10] was used to study 32,183
lncRNA transcripts belonging to 17,512 lncRNAs. Back-
ground substracted and normalized (log2-based) expres-
sion data were provided from Biogazelle for further data
analysis. Expression data of lncRNAs for ccRCC and nor-
mal tissues was groupwise normalized deducting group
mean value. Pairwise fold change, for each gene, was calcu-
lated by dividing ccRCC group mean of RNA expression
level by normal group mean of expression levels. Pearson’s
correlation coefficient was used for correlation analyses
(R-Base Package v3.0.2). A heatmap was created using
gplots v2.12.1 and RColorBrewer v1.0-5.Real-time PCR
Quantitative real-time PCR was performed to validate
the microarray experiments using an independent cohort
of 55 ccRCC and 52 normal renal tissue samples and to
confirm the success of siRNA-mediated lncRNA knock-
down. Complementary DNA (cDNA) was synthesized
with 1 μg RNA using the PrimeScript RT Reagent Kit
with gDNA Eraser. Real-time PCR was performed with
5 ng cDNA template using the 1× SYBR Premix Ex Taq
II with ROX Plus and 10 pmol/μl PCR primers (see
Additional file 3: Table S1 for primer sequences); all re-
agents were from Takara Bio, Saint-Germain-en-Laye,
France. PCR was performed using an ABIPrism 7900
HT Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Data analysis was performed
using Qbase + (Biogazelle) with PPIA and ACTB as
reference genes in the 2-ΔΔCT algorithm. SPSS Statistics
v21 (IBM, Ehningen, Germany) was used for statis-
tical analyses (Mann–Whitney-U test, Cox regression
analysis).MicroRNA quantification
Quantitative real-time PCR was used to determine the
tissue levels of several FOXG1-2 microRNA targets in
each ten normal and malignant renal tissues using the
Qiagen miScript SYBR Green PCR technology (Hilden,
Germany): 1,000 ng total RNA was reverse transcribed
and real-time PCR was performed with 5 ng cDNA tem-
plate. Pre-designed miScript Primer Assays for miR-519a,
miR-519b, miR-519c, miR-548, miR-3120, miR-4284, miR-
4658, and SNORD43 were used. PCR was performed
using the ABIPrism 7900 HT Fast Real-Time PCR System.
Data analysis was performed using Qbase + with
SNORD43 as reference genes in the 2-ΔΔCT algorithm.
IBM SPSS Statistics v21 was used for statistical analyses
(Pearson correlation test).
Blondeau et al. Clinical Epigenetics  (2015) 7:10 Page 10 of 10In silico analyses
The MiRTarget2 algorithm [9] was used to predict
microRNA seeds within the validated lncRNA tran-
scripts. Potential lncRNA-protein interactions were de-
termined using the catRAPID omics algorithm [11]. The
cellular functions of proteins were retrieved with Gene-
MANIA [12]. Standard settings were used in all software
packages.
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article are available in the Gene Expression Omnibus re-
pository (data entry: GSE61763).
Additional files
Additional file 1: Table S2. Summary of predicted lncRNA-protein
interactions (catRAPID omics algorithm).
Additional file 2: Table S3. Summary of lncRNA interacting networks
for cellular functions (GeneMANIA algorithm).
Additional file 3: Table S1. List of PCR primers.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JJCB and DS carried out the lncRNA and microRNA expression analyses. MD
performed the statistical analysis of microarray data. DS, IS, and SS performed
the siRNA experiments. JJCB and JE performed the statistics and drafted the
manuscript. SP and SCM participated in the study design and helped to draft
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The collection of tissue samples was performed within the framework of the
Biobank of the Center for Integrated Oncology Köln Bonn.
Author details
1Department of Urology, University Hospital Bonn, Bonn, Germany. 2Institute
of Pathology, University Hospital Bonn, Bonn, Germany. 3Department of
Prostate Cancer Research, University Hospital Bonn, Bonn, Germany. 4Center
of Integrated Oncology, University Hospital Bonn, Bonn, Germany.
Received: 15 October 2014 Accepted: 15 January 2015
References
1. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney
cancer. Nat Rev Urol. 2010;7:245–57.
2. Dietrich D, Meller S, Uhl B, Ralla B, Stephan C, Jung K, et al. Nucleic
acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci.
2014:1–27.
3. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions
in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14:699–712.
4. Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM, Kennett JY, et al. Human
cancer long non-coding RNA transcriptomes. PLoS One. 2011;6:e25915.
5. Qin C, Han Z, Qian J, Bao M, Li P, Ju X, et al. Expression pattern of long
non-coding RNAs in renal cell carcinoma revealed by microarray. PLoS One.
2014;9:e99372.
6. Yu G, Yao W, Wang J, Ma X, Xiao W, Li H, et al. lncRNAs expression
signatures of renal clear cell carcinoma revealed by microarray. PLoS One.
2012;7:e42377.
7. Fachel AA, Tahira AC, Vilella-Arias SA, Maracaja-Coutinho V, Gimba ER, Vignal
GM, et al. Expression analysis and in silico characterization of intronic long
noncoding RNAs in renal cell carcinoma: emerging functional associations.
Mol Cancer. 2013;12:140.8. Malouf GG, Zhang J, Yuan Y, Comperat E, Roupret M, Cussenot O, et al.
Characterization of long non-coding RNA transcriptome in clear-cell renal
cell carcinoma by next-generation deep sequencing. Mol Oncol. 2014.
9. Wang X, El Naqa IM. Prediction of both conserved and nonconserved
microRNA targets in animals. Bioinformatics (Oxford, England). 2008;24:325–32.
10. Volders PJ, Helsens K, Wang X, Menten B, Martens L, Gevaert K, et al.
LNCipedia: a database for annotated human lncRNA transcript sequences
and structures. Nucleic Acids Res. 2013;41:D246–51.
11. Agostini F, Zanzoni A, Klus P, Marchese D, Cirillo D, Tartaglia GG. catRAPID
omics: a web server for large-scale prediction of protein-RNA interactions.
Bioinformatics (Oxford, England). 2013;29:2928–30.
12. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al.
The GeneMANIA prediction server: biological network integration for gene
prioritization and predicting gene function. Nucleic Acids Res. 2010;38:
W214–20.
13. Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T, Calin GA.
Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol.
2013;65:1140–51.
14. Qiao HP, Gao WS, Huo JX, Yang ZS. Long non-coding RNA GAS5 functions
as a tumor suppressor in renal cell carcinoma. Asian Pac J Cancer Prev.
2013;14:1077–82.
15. Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript
overexpressed in human renal cancer and during hypoxia. J Natl Cancer
Inst. 1999;91:143–51.
16. Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N. Comparative
effectiveness review: prostate cancer antigen 3 testing for the diagnosis and
management of prostate cancer. J Urol. 2013;190:389–98.
17. Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the
detection of hepatocellular carcinoma. BioMed Res Int. 2013;2013:136106.
18. Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, et al.
Circulating long non-coding RNAs in plasma of patients with gastric cancer.
Anticancer Res. 2013;33:3185–93.
19. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding RNA
metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA
as a novel plasma-based biomarker for diagnosing prostate cancer.
Eur J Cancer (Oxford, England: 1990). 2013;49:2949–59.
20. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 2010;464:1071–6.
21. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, et al. The long
noncoding RNA SChLAP1 promotes aggressive prostate cancer and
antagonizes the SWI/SNF complex. Nat Genet. 2013;45:1392–8.
22. Tani H, Mizutani R, Salam KA, Tano K, Ijiri K, Wakamatsu A, et al. Genome-wide
determination of RNA stability reveals hundreds of short-lived noncoding
transcripts in mammals. Genome Res. 2012;22:947–56.
23. Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini E, Moscato P,
et al. Genome-wide analysis of long noncoding RNA stability. Genome Res.
2012;22:885–98.
24. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long
non-coding RNA, HULC expression through interaction with microRNA-372
in liver cancer. Nucleic Acids Res. 2010;38:5366–83.
25. Zhu J, Fu H, Wu Y, Zheng X. Function of lncRNAs and approaches to
lncRNA-protein interactions. Sci China Life Sci. 2013;56:876–85.
26. Zhang B, Gunawardane L, Niazi F, Jahanbani F, Chen X, Valadkhan S.
A novel RNA motif mediates the strict nuclear localization of a long
noncoding RNA. Mol Cell Biol. 2014;34:2318–29.
27. Ploner A, Ploner C, Lukasser M, Niederegger H, Huttenhofer A.
Methodological obstacles in knocking down small noncoding RNAs. RNA
(New York, NY). 2009;15:1797–804.
